gliclazide has been researched along with Carcinoma, Pancreatic Ductal in 1 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sliwinska, A | 1 |
| Sliwinski, T | 1 |
| Kasznicki, J | 1 |
| Drzewoski, J | 1 |
1 other study available for gliclazide and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells.
Topics: Adolescent; Adult; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DNA; DNA Damage; DNA Repair; Gene | 2010 |